ClinicalTrials.gg
RecruitingNCT06515652Updated Jul 23, 2024

To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome

An interventional study of rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun in Metabolic Syndrome, sponsored by Hamdard University. Recruiting at 1 site in Pakistan. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by Hamdard University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Sep 2023, registered Jul 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.

Planned enrollment
3rd of 16
200 · median 60
Started
2023
with 2 others
No phase
14 of 16
6 open now
Registered
9th of 16
by date
Lead sponsor
1 of 16
Hamdard University

Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2023, is one of 14 with no phase, and was the 9th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Metabolic Syndrome with a site in Pakistan, or all of them as a file.
02

Study summary

Metabolic syndrome is an important global public health problem and comprises a group of complex risk factors, including obesity, dyslipidemia, hyperglycemia, and hypertension. One of the main diagnostic components of metabolic syndrome is obesity, which is usually measured by the waist circumference and the intra-abdominal visceral fat, in addition to dyslipidemia (the condition of raised triglycerides and reduced high density lipoprotein (HDL)-cholesterol in blood; other components are raised blood pressure and fasting plasma glucose, all of which are related to weight gain.

Metabolic syndrome is related to cardio metabolic risk factors and lipid disorders. Worldwide, cardiovascular diseases (CVD) are the leading cause of mortality and morbidity. It is expected that by 2030, mortality from CVD will reach 22.5 million people, compared with 17.5 million deaths in 2012.

Major pharmacological interventions include management of dyslipidemia with statins, decreasing prothrombotic risk with antiplatelet drugs, and the use of insulin sensitizers to decrease the risk of diabetes. In addition to non-pharmacologic interventions that improve BP, pharmacological agents provide the primary basis for hypertension management in the majority of patients. Among major antihypertensive agents, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide (or thiazide-like) diuretics are preferentially recommended in the general condition because of their additional cardiovascular protection effects and/or accessibility.

Herbal drugs are being used worldwide in the management of metabolic syndrome now a days. Some of the herbs e.g. Terminalia arjuna, Trigonella Foenum-graecum, Allium Sativum, Cinnamon verum and Zingiber Officinale are being used very effectively in managing metabolic syndrome.

METHODOLOGY:

The basic purpose of this study will be to explore a poly herbal combination for effective and safe management of metabolic syndrome. This is a multicenter; prospective study will be conducted in the department of Pharmacology, HCMD in collaboration with Hamdard University Hospital, National Medical Center and Amna Unani Hospital.

After fulfilling the inclusion and exclusion criteria a total of 200 patients will be enrolled and divided in 2 groups. One group will be given allopathic combination while the other group will be given a poly herbal formulation. Important parameters include BMI, Systolic and Diastolic blood pressure, lipid profile, HbA1c, S.creatinine, Urinary Albumin, Urinary Creatinine, ALT \& AST. Follow up will be done at day 0, 30, 60 \& 90th of treatment. The data will be recorded in a tabulated form and statistical analysis will be done at the end of the study to see the significance of the two studies.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Hyperlipidemia
  • Type 2 Diabetes
  • Hypertension
  • Obesity
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ageing between 35-65 years;
  • Patients with a diagnosis of metabolic syndrome according to the criteria of IDF 2005

Exclusion criteria

Exclusion Criteria:

  • Pregnant \& lactating female
  • Use of insulin or sulfonamide derivative oral antidiabetic drugs
  • Doing heavy physical activity or working in a physically demanding job
  • Presence of liver or kidney disease, or immune deficiency
  • Patients with history of myocardial infarction, coronary artery bypass surgery, unstable angina \& cardiac failure.
  • Conditions that will seriously affect weight management such as having had bariatric surgery
  • Determined to have had an unintentional sudden weight loss of more than 5% in the last three months
  • Intellectual disability or significant medical or psychiatric illness as documented by the referring doctor.
  • Any to the use of drugs involved in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Allopathic

    1. Tablet.Rosuvastatin 10mg once daily for 3 months 2. Tablet. Telmisartan 40mg once daily for 3 months 3. Tablet. Sitagliptin / Metformin 50/500mg once daily for 3 months

    Drug: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun

  • Active comparator
    Herbal

    1. Cinammon powder 2 gm once daily for 3 months 2. Garlic powder 1 gm once daily for 3 months 3. Ginger powder 4 gm once daily for 3 months 4. Fenugreek powder 10 gm once daily for 3 months 5. Arjuna 2 gm once daily for 3 months

    Drug: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun

Interventions

  • Drugrosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun

    Comparing allopathic and herbal group of drugs for metabolic syndrome

06

What researchers measure

Primary outcomes

  1. Glycosylated hemoglobin

    at day 0 and day 90

    Time frame: 3 months

  2. Systolic blood pressure, diastolic blood pressure

    at day 0, day 30, day 60 and day 90

    Time frame: 3 months

  3. triglyceride level

    at day 0, day 30, day 60 and day 90

    Time frame: 3 months

  4. high density lipoprotein level

    at day 0, day 30, day 60 and day 90

    Time frame: 3 months

  5. waist hip ratio

    at day 0 and day 90

    Time frame: 3 months

Secondary outcomes

  1. Fasting blood sugar, random blood sugar

    at day 0, day 30, day 60 and day 90

    Time frame: 3 months

  2. serum cholesterol level

    at day 0, day 30, day 60 and day 90

    Time frame: 3 months

  3. serum creatinine level

    at day 0, day 30, day 60 and day 90

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Prof. Dr. M. Sajid Abbas Jaffri
    Karachi, Sindh 75600, Pakistan
    Recruiting
    • Shiraz M Siddiqui, PhD · Contact
    • Syeda A Zaidi, MBBS MPhil · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jul 2024, 10 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 23, 2024
StartActual
Sep 1, 2023
Primary completionEst.
Jul 30, 2024
CompletionEst.
Aug 30, 2024
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06515652
Lead sponsor
Hamdard University
Responsible party
SYEDA AMBER ZAIDI (Assitstant Professor, Hamdard University) — Principal investigator
First posted
Jul 23, 2024
Start date
Sep 1, 2023
Primary completion
Jul 30, 2024 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
Jul 23, 2024

Study contacts

Syeda Amber Zaidi, MBBS MPhil
Contact
amberzaidi36@gmail.com
03323188867
Syed Mohsin Turab, MBBS MPhil PhD
Contact
mohsin.turab@hamdard.edu.pk
03332115515

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion